Welcome to our dedicated page for Maravai Lifesciences Holdings SEC filings (Ticker: MRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Maravai LifeSciences Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed life sciences operating company with Class A common stock. Form 8-K reports furnish quarterly and annual financial results, including revenue, net loss, adjusted EBITDA and business updates for the TriLink nucleic acid synthesis and Cygnus biologics safety testing operations.
The company’s proxy materials describe annual meeting matters, director elections, independent auditor ratification, executive compensation votes and board governance. Other current reports record leadership succession, board-size and committee changes, equity-award treatment, and restructuring actions classified as exit or disposal activities, including related cost disclosures and risk language.
Form 4 snapshot: On 18 Jun 2025, Director Sean Laurence Cunningham filed a Form 4 disclosing an equity award from Maravai LifeSciences Holdings, Inc. (ticker MRVI).
Key transaction details: On 16 Jun 2025, Cunningham acquired 89,139 Class A common shares in the form of restricted stock units (RSUs) granted under the company’s 2020 Omnibus Incentive Plan at an indicated price of $2.16 per share. The RSUs vest in full on the earlier of one year from grant or the date of the 2026 annual meeting.
Post-grant ownership: The filing reports 138,055 shares held directly following the award. However, the footnote explains that these shares are held for the benefit of a GTCR-affiliated entity; Cunningham disclaims any pecuniary interest and is therefore not treated as the economic owner for Section 16 purposes.
Nature of the filing: No open-market purchase or sale occurred, and no derivative securities were involved. This is a routine board compensation grant rather than a signaling transaction. The filing does not contain earnings information, strategic announcements, or changes in control.
Form 4 filed for Maravai LifeSciences Holdings, Inc. (MRVI) discloses that director Jessica Hopfield received 89,139 Class A common-stock restricted stock units (RSUs) on 16 June 2025 under the company’s 2020 Omnibus Incentive Plan. The RSUs will vest in full on the earlier of one year from the grant date or the 2026 annual stockholders’ meeting. Following the award, Hopfield now reports 199,907 shares held directly. Transaction code “A” confirms the award was an acquisition, not an open-market purchase or sale. No derivative securities were involved, and there were no dispositions. Overall, the filing represents a routine equity incentive grant aligning director compensation with shareholder interests.